Incyte (NASDAQ:INCY) is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Its operations span across various phases of drug development, from research to bringing innovative medicines to market, targeting a range of diseases, including oncology and inflammation. The company's projects often involve collaborations with other pharmaceutical entities to leverage combined expertise, aiming to accelerate the development of new treatments that can offer significant improvements over existing therapies. Incyte's objectives include advancing its pipeline of potential therapies, maintaining a robust research and development program, and expanding its product portfolio to address unmet medical needs, ultimately striving to enhance patient care and shareholder value.